

重庆大学药学院

学术报告第一百〇七讲

报告题目: Genomics in Drug Development

报告人: 顾之杰 博士 (*GeneCore Bio Technologies*)

时 间: 2017年11月30日(周四) 10:10

地 点: 重庆大学药学院学术报告厅

报告人简历:

Dr. Gu was trained in the Human Genome Project (HGP) and specialized in human DNA mutations, including SNPs (single nucleotide polymorphisms). He pioneered SNP discovery on a genome wide scale, and developed innovative genotyping technologies. Over the ten five years, he has focused on applying genomic biomarker technologies, ReAL (Renascions Association Links), to pharmaceutical uses, particularly in drug development and toxicity. Dr. Gu led development and commercialization of the CodeLink Human P450 Mutations Bioarray for drug development and dosage determination. He also led development of a series of companion IVD, including “HepaType” and “AsthmaType”, and obtained regulatory approvals. He championed clinical development of natural human interferon for HCV (hepatitis C virus) and HBV (hepatitis B virus). Dr. Gu earned his PhD in bioinorganic chemistry and biophysics, and has published more than twenty peer reviewed articles and book chapters, and holds one issued patent on human P450 mutation detection.



Dr. Gu has a long history with SNP science and technology, and extensive experience applying this knowledge to the specific challenge of rescuing drugs. He directed research at GeneCore BioTechnologies, a company acquired from Celera Genomics by Vita Genomics, where he successfully developed their “IressaType” companion IVD for AstraZeneca’s Iressa (gefitinib), for its NSCLC (non-small cell lung cancer) indication. The drug was re-approved by EMEA (European Medicine Evaluation Agency) in 2009, after limitation warnings were enforced by the US FDA in December 2004. Dr. Gu also led Vita Genomics teams to develop their “HepaType” companion IVD for interferon (IFN) treatment for HCV patients. In past, Dr. Gu worked on

Troxatyl, a nucleoside analogue, for AML (acute myeloid leukemia), to increase its efficacy from 18% to 55% in retrospective analysis. Recently, Renascions worked with Janssen Pharmaceuticals (J&J) and Ionas Pharmaceuticals on cardiovascular drugs and oncological drugs.